From maps to mechanisms through neuroimaging of schizophrenia

Nature

Volumn 468, Issue 7321, 2010, Pages 194-202

  Meyer Lindenberg, Andreas ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CALCIUM CHANNEL L TYPE; CATECHOL METHYLTRANSFERASE; DISRUPTED IN SCHIZOPHRENIA 1 PROTEIN; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; NEU DIFFERENTIATION FACTOR; OLANZAPINE; TOLCAPONE; ZINC FINGER PROTEIN;

BRAIN; FUTURE PROSPECT; GENETIC ANALYSIS; PSYCHOLOGY;

BRAIN NERVE CELL; COGNITION; DISEASE PREDISPOSITION; DOPAMINERGIC TRANSMISSION; ELECTROENCEPHALOGRAPHY; EMOTION; ENVIRONMENTAL FACTOR; EPIGENETICS; EPISODIC MEMORY; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GABAERGIC SYSTEM; GENE DELETION; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; HIPPOCAMPUS; HUMAN; MAGNETOENCEPHALOGRAPHY; NERVE CELL DIFFERENTIATION; NEUROANATOMY; NEUROIMAGING; NONHUMAN; OSCILLATION; POSITRON EMISSION TOMOGRAPHY; PREFRONTAL CORTEX; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; PYRAMIDAL NERVE CELL; REVIEW; REWARD; SCHIZOPHRENIA; SELECTIVE ATTENTION; SINGLE NUCLEOTIDE POLYMORPHISM; WORKING MEMORY;

BRAIN MAPPING; ENVIRONMENT; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MOLECULAR IMAGING; PSYCHOTIC DISORDERS; SCHIZOPHRENIA;

EID: 78149422984     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature09569     Document Type: Review

References (112)

1. Editorial. A decade for psychiatric disorders. Nature 463, 9 (2010).
2. Weinberger, D. R.Implications of normal brain development for the pathogenesis of schizophrenia. Arch. Gen. Psychiatry 44, 660-669 (1987).
3. Ellison-Wright, I., Glahn, D. C., Laird, A. R., Thelen, S. M. & Bullmore, E. The anatomy of first-episode and chronic schizophrenia: an anatomical likelihood estimation meta-analysis. Am. J. Psychiatry 165, 1015-1023 (2008).
4. Boos, H. B., Aleman, A., Cahn, W., Hulshoff Pol, H. & Kahn, R. S. Brain volumes in relatives of patients with schizophrenia: a meta-analysis. Arch. Gen. Psychiatry 64, 297-304 (2007).
5. Goldman, A. L. et al. Heritability of brain morphology related to schizophrenia: a large-scale automated magnetic resonance imaging segmentation study. Biol. Psychiatry 63, 475-483 (2008).
6. Lewis, D. A. & Sweet, R. A. Schizophrenia from a neural circuitry perspective: advancing toward rational pharmacological therapies.J.Clin. Invest. 119, 706-716 (2009).
7. Selemon, L. D. & Goldman-Rakic, P. S. The reduced neuropil hypothesis: a circuit based model of schizophrenia. Biol. Psychiatry 45, 17-25 (1999).
8. Hashimoto, T. et al. Gene expression deficits in a subclass of GABA neurons in the prefrontal cortex of subjects with schizophrenia. J. Neurosci. 23, 6315-6326 (2003).
9. Byne, W., Hazlett, E. A., Buchsbaum, M. S. & Kemether, E. The thalamus and schizophrenia: current status of research. Acta Neuropathol. 117, 347-368 (2009).
10. Goldman-Rakic, P. S. Cellular basis of working memory. Neuron 14, 477-485 (1995).
11. Goldman-Rakic, P. S. Working memory dysfunction in schizophrenia. J. Neuropsychiatry Clin. Neurosci. 6, 348-357 (1994).
12. Callicott, J.H.et al.Physiologicaldysfunctionofthe dorsolateralprefrontal cortex in schizophrenia revisited. Cereb. Cortex, 10, 1078-1092, (2000).
13. Tan, H. Y. et al. Dysfunctional prefrontal regional specialization and compensation in schizophrenia. Am. J. Psychiatry 163, 1969-1977 (2006).
14. Fusar-Poli, P. et al. Neurofunctional correlates of vulnerability to psychosis: a systematic review and meta-analysis. Neurosci. Biobehav. Rev. 31, 465-484 (2007).
15. Achim, A. M. & Lepage, M. Episodic memory-related activation in schizophrenia: meta-analysis. Br. J. Psychiatry 187, 500-509 (2005).
16. Murray, G. K. et al. Substantia nigra/ventral tegmental reward prediction error disruption in psychosis. Mol. Psychiatry 13, 267-276 (2008).
17. Juckel, G. et al. Dysfunction of ventral striatal reward prediction in schizophrenia. Neuroimage 29, 409-416 (2006).
18. Simon, J. J. et al. Neural correlates of reward processing in schizophrenia-Relationship to apathy and depression. Schizophr. Res. 118, 154-161 (2009).
19. Aleman, A.& Kahn, R.S.Strange feelings: doamygdala abnormalities dysregulate the emotional brain in schizophrenia? Prog. Neurobiol., 77, 283-298, (2005).
20. Rasetti, R. et al. Evidence that altered amygdala activity in schizophrenia is related to clinical state and not genetic risk. Am. J. Psychiatry 166, 216-225 (2009).
21. Gur, R. E. et al. Limbic activation associated with misidentification of fearful faces and flat affect in schizophrenia. Arch. Gen. Psychiatry 64, 1356-1366 (2007).
22. Brunet-Gouet, E. & Decety, J. Social brain dysfunctions in schizophrenia: a review of neuroimaging studies. Psychiatry Res. 148, 75-92 (2006).
23. Walter, H. Dysfunctionofthe social brain ismodulated byintention type:an FMRI study. Soc. Cogn. Affect. Neurosci. 4, 166-176 (2009).
24. Dierks, T. et al. Activation of Heschl's gyrus during auditory hallucinations. Neuron 22, 615-621 (1999).
25. Hubl, D. et al. Pathways that make voices: white matter changes in auditory hallucinations. Arch. Gen. Psychiatry 61, 658-668 (2004).
26. Wolf, R.C.et al. Temporally anticorrelated brainnetworks during working memory performance reveal aberrant prefrontal and hippocampal connectivityinpatients with schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 33, 1467-1473 (2009).
27. Whitfield-Gabrieli, S. et al. Hyperactivity and hyperconnectivity of the default network in schizophrenia and in first-degree relatives of persons with schizophrenia. Proc. Natl Acad. Sci. USA 106, 1279-1284 (2009).
28. Meyer-Lindenberg, A. S. et al. Regionally specific disturbance of dorsolateral prefrontal-hippocampal functional connectivity in schizophrenia. Arch. Gen. Psychiatry 62, 379-386 (2005).
29. Crossley, N. A. et al. Superior temporal lobe dysfunction and frontotemporal dysconnectivity in subjects at risk of psychosis and in first-episode psychosis. Hum. Brain Mapp. 30, 4129-4137 (2009).
30. Meyer-Lindenberg, A. et al. Evidence for abnormal cortical functional connectivity during working memory in schizophrenia. Am. J. Psychiatry 158, 1809-1817 (2001).
31. Friston, K. J., Frith, C. D., Fletcher, P., Liddle, P. F. & Frackowiak, R. S. Functional topography: multidimensional scaling and functional connectivity in the brain. Cereb. Cortex 6, 156-164 (1996).
32. Bullmore, E. & Sporns, O. Complex brain networks: graph theoretical analysis of structural and functional systems. Nature Rev. Neurosci. 10, 186-198 (2009).
33. Bassett, D. S. et al. Hierarchical organization of human cortical networks in health and schizophrenia. J. Neurosci. 28, 9239-9248 (2008).
34. Bertolino, A. et al. Altered development of prefrontal neurons in rhesus monkeys with neonatal mesial temporo-limbic lesions: a proton magnetic resonance spectroscopic imaging study. Cereb. Cortex 7, 740-748 (1997).
35. Braff, D. L. & Geyer, M. A. Sensorimotor gating and schizophrenia. Human and animal model studies. Arch. Gen. Psychiatry 47, 181-188 (1990).
36. Jaskiw, G. E., Karoum, F. K. & Weinberger, D. R. Persistent elevations in dopamine and its metabolitesin the nucleus accumbens after mild subchronic stress inrats with ibotenic acid lesions of the medial prefrontal cortex. Brain Res. 534, 321-323 (1990).
37. Seeman, P. & Lee, T. Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. Science 188, 1217-1219 (1975).
38. Davis, K. L., Kahn, R. S., Ko, G. & Davidson, M. Dopamine in schizophrenia: a review and reconceptualization. Am. J. Psychiatry 148, 1474-1486 (1991).
39. Laruelle, M.Imaging dopamine transmission in schizophrenia.Areview and meta-analysis. Q. J. Nucl. Med. 42, 211-221 (1998).
40. Howes, O.D. et al. Elevated striatal dopamine function linked toprodromal signs of schizophrenia. Arch. Gen. Psychiatry 66, 13-20 (2009).
41. Meyer-Lindenberg, A. et al. Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia. Nature Neurosci. 5, 267-271 (2002).
42. Fusar-Poli, P. et al. Abnormal prefrontal activation directly related to pre-synaptic striatal dopamine dysfunction in people at clinical high risk for psychosis. Mol. Psychiatry doi:10.1038/mp.2009.108 (1 December 2009).
43. Kapur, S. Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. Am. J. Psychiatry 160, 13-23 (2003).
44. Munafo, M. R., Brown, S. M. & Hariri, A. R. Serotonin transporter (5-HTTLPR) genotype and amygdala activation: a meta-analysis. Biol. Psychiatry 63, 852-857 (2008).
45. Mier, D., Kirsch, P. & Meyer-Lindenberg, A. Neural substrates of pleiotropic action of genetic variation inCOMT: a meta-analysis. Mol. Psychiatry 15, 918-927 (2010).
46. Purcell, S. M. et al. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 460, 748-752 (2009).
47. Nicodemus, K. K. et al. Evidence of statistical epistasis between DISC1, CIT and NDEL1 impacting risk for schizophrenia: biological validation with functional neuroimaging. Hum. Genet. 127, 441-452 (2010).
48. Liu, J. et al. Combining fMRI and SNP data to investigate connections between brain function and genetics using parallel ICA. Hum. Brain Mapp. 30, 241-255 (2009).
49. Gottesman, I. I. & Gould, T. D. The endophenotype concept in psychiatry: etymology and strategic intentions. Am. J. Psychiatry 160, 636-645 (2003).
50. Fan, J. B. et al. Catechol-O-methyltransferase gene Val/Met functional polymorphism and risk of schizophrenia: a large-scale association study plus meta-analysis. Biol. Psychiatry 57, 139-144 (2005).
51. Stefansson, H. et al. Common variants conferring risk of schizophrenia. Nature 460, 744-747 (2009).
52. Shi, J. et al. Common variants on chromosome 6p22.1 are associated with schizophrenia. Nature 460, 753-757 (2009).
53. Egan, M.F.et al. EffectofCOMT Val108/158Metgenotypeonfrontal lobefunction and risk for schizophrenia. Proc. Natl Acad. Sci. USA 98, 6917-6922 (2001).
54. Gogos, J. A. et al. Catechol-O-methyltransferase-deficient mice exhibit sexually dimorphic changesincatecholamine levels and behavior.Proc. Natl Acad. Sci. USA 95, 9991-9996 (1998).
55. Chen, J. et al. Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain. Am. J. Hum. Genet. 75, 807-821 (2004).
56. Honea, R. et al. Impact of interacting functional variants in COMT on regional gray matter volume in human brain. Neuroimage 45, 44-51 (2009).
57. Meyer-Lindenberg, A. et al. Midbrain dopamine and prefrontal function in humans: interaction and modulation by COMT genotype. Nature Neurosci. 8, 594-596 (2005).
58. Stefansson, H. et al. Neuregulin 1 and susceptibility to schizophrenia. Am. J. Hum. Genet. 71, 877-892 (2002).
59. Barros, C.S. et al. Impaired maturation of dendritic spines without disorganization of cortical cell layers in mice lacking NRG1/ErbB signaling in the central nervous system. Proc. Natl Acad. Sci. USA 106, 4507-4512 (2009).
60. Mei, L. & Xiong, W. C. Neuregulin 1 in neural development, synaptic plasticity and schizophrenia. Nature Rev. Neurosci. 9, 437-452 (2008).
61. Hall, J. et al. A neuregulin 1 variant associated with abnormal cortical function and psychotic symptoms. Nature Neurosci. 9, 1477-1478 (2006).
62. Gruber, O. et al. Neuregulin-1 haplotype HAP(ICE) is associated with lower hippocampal volumes in schizophrenic patients and in non-affected family members. J. Psychiatr. Res. 43, 1-6 (2008).
63. Mata, I. et al. A neuregulin 1 variant is associated with increased lateral ventricle volume in patients with first-episode schizophrenia. Biol. Psychiatry 65, 535-540 (2009).
64. McIntosh, A. M. et al. The effects of a neuregulin 1 variant on white matter density and integrity. Mol. Psychiatry 13, 1054-1059 (2008).
65. Millar, J. K. et al. Disruption of two novel genes by a translocation co-segregating with schizophrenia. Hum. Mol. Genet. 9, 1415-1423 (2000).
66. Ishizuka, K., Paek, M., Kamiya, A. & Sawa, A. A review of Disrupted-In-Schizophrenia-1 (DISC1): neurodevelopment, cognition, and mental conditions. Biol. Psychiatry 59, 1189-1197 (2006).
67. Callicott, J. H. et al. Variation in DISC1 affects hippocampal structure and function and increases risk for schizophrenia. Proc. Natl Acad. Sci. USA 102, 8627-8632 (2005).
68. Prata, D. P. et al. Effect of disrupted-in-schizophrenia-1 on pre-frontal cortical function. Mol. Psychiatry 13, 915-917 (2008).
69. Di Giorgio, A. et al. Association of the SerCys DISC1 polymorphism with human hippocampal formation gray matter andfunction during memory encoding. Eur. J. Neurosci. 28, 2129-2136 (2008).
70. Cannon, T. D. et al. Association of DISC1/TRAX haplotypes with schizophrenia, reducedprefrontal gray matter, andimpaired short-andlong-term memory. Arch. Gen. Psychiatry 62, 1205-1213 (2005).
71. Nicodemus, K. K. et al. Evidence for statistical epistasis between catechol-O-methyltransferase (COMT) and polymorphisms in RGS4, G72 (DAOA), GRM3, and DISC1: influence on risk of schizophrenia. Hum. Genet. 120, 889-906 (2007).
72. Harrison, P. J. & Weinberger, D. R. Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol. Psychiatry 10, 40-68 (2005).
73. Garcia, R. A., Vasudevan, K. & Buonanno, A. The neuregulin receptor ErbB-4 interacts with PDZ-containing proteins at neuronal synapses. Proc. Natl Acad. Sci. USA 97, 3596-3601 (2000).
74. Mata, I. et al. Additive effect of NRG1 and DISC1 genes on lateral ventricle enlargement in first episode schizophrenia. Neuroimage 53, 1016-1022 (2009).
75. O'Donovan, M. C. et al. Identification of loci associated with schizophrenia by genome-wide association and follow-up. Nature Genet. 40, 1053-1055 (2008).
76. Esslinger, C. et al. Neural mechanisms of a genome-wide supported psychosis variant. Science 324, 605 (2009).
77. Walters, J. T. et al. Psychosis susceptibility gene ZNF804A and cognitive performance in schizophrenia. Arch. Gen. Psychiatry 67, 692-700 (2010).
78. Lencz, T. et al. A schizophrenia risk gene, ZNF804A, influences neuroanatomical and neurocognitive phenotypes. Neuropsychopharmacology 35, 2284-2291 (2010).
79. Walter, H. et al. Effects of a genome-wide supported psychosis risk variant on neural activation during a theory-of-mind task. Mol. Psychiatry doi:10.1038/ mp.2010.18 (16 March 2010).
80. Ferreira, M.A.et al. Collaborative genome-wide association analysis supportsa role for ANK3 andCACNA1Cinbipolar disorder.Nature Genet., 40, 1056-1058, (2008).
81. Erk, S.et al. Brain function incarriersofagenome-wide supported bipolar disorder variant. Arch. Gen. Psychiatry 67, 803-811 (2010).
82. Wessa, M. et al. The CACNA1C risk variant for bipolar disorder influences limbic activity. Mol. Psychiatry doi:10.1038/mp.2009.103 (30 March 2010).
83. Ben-Shachar, S.et al. Microdeletion 15q13.3:a locus with incomplete penetrance for autism, mental retardation, and psychiatric disorders. J. Med. Genet. 46, 382-388 (2009).
84. Karayiorgou, M., Simon, T. J. & Gogos, J. A. 22q11.2 microdeletions: linking DNA structural variation to brain dysfunction and schizophrenia. Nature Rev. Neurosci. 11, 402-416 (2010).
85. Meechan, D. W., Maynard, T. M., Gopalakrishna, D., Wu, Y. & LaMantia, A. S. When half isnot enough: gene expression and dosagein the 22q11 deletion syndrome. Gene Expr. 13, 299-310 (2007).
86. Kempf, L. et al. Functional polymorphisms in PRODH are associated with risk and protection for schizophrenia and fronto-striatal structure and function. PLoS Genet. 4, e1000252 (2008).
87. Lieberman, J. A., Sheitman, B. B. & Kinon, B. J. Neurochemical sensitization in the pathophysiology ofschizophrenia: deficits and dysfunctioninneuronal regulation and plasticity. Neuropsychopharmacology 17, 205-229 (1997).
88. Selten, J. P. & Cantor-Graae, E. Social defeat: risk factor for schizophrenia? Br. J. Psychiatry 187, 101-102 (2005).
89. 11C]raclopride. J. Neurosci. 24, 2825-2831 (2004).
90. 11C]raclopride PET study. Neuropsychopharmacology, 33, 2033-2041, (2008).
91. Zink, C. F. et al. Know your place: neural processing of social hierarchy in humans. Neuron 58, 273-283 (2008).
92. Caspi, A. et al. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O- methyltransferase Gene: longitudinal evidence of a gene 3 environment interaction. Biol. Psychiatry 57, 1117-1127 (2005).
93. 11C]-raclopride binding after THC challenge. Neuroimage 52, 1521-1527 (2010).
94. Insel, T. R. & Scolnick, E. M. Cure therapeutics and strategic prevention: raising the bar for mental health research. Mol. Psychiatry 11, 11-17 (2006).
95. Durstewitz, D. & Seamans, J. K. The dual-state theory of prefrontal cortex dopamine fun ction with relevancetocatechol-o-methyltransferasegeno types and schizophrenia. Biol. Psychiatry 64, 739-749 (2008).
96. Apud, J.A. et al. Tolcapone improves cognition and cortical information processing in normal human subjects. Neuropsychopharmacology 32, 1011-1020 (2007).
97. Bertolino, A. et al. Interaction of COMT (Val(108/158)Met) genotype and olanzapine treatment on prefrontal cortical function in patients with schizophrenia. Am. J. Psychiatry 161, 1798-1805 (2004).
98. Sigurdsson, T., Stark, K. L., Karayiorgou, M., Gogos, J. A. & Gordon, J. A. Impaired hippocampal-prefrontal synchrony in a genetic mouse model of schizophrenia. Nature 464, 763-767 (2010).
99. Tost, H. et al. Acute D2 receptor blockade induces rapid, reversible remodeling in human cortical-striatal circuits. Nature Neurosci. 13, 920-922 (2010).
100. Buzsaki, G. & Draguhn, A. Neuronal oscillations in cortical networks. Science 304, 1926-1929 (2004).
101. Sohal, V.S., Zhang, F., Yizhar, O.&Deisseroth, K.Parvalbumin neurons and gamma Rhythms enhance cortical circuit performance. Nature 459, 698-702 (2009).
102. Von Stein, A., Chiang, C. & Konig, P. Top-down processing mediated by interareal Synchronization. Proc. Natl Acad. Sci. USA 97, 14748-14753 (2000).
103. Lisman, J.&Buzsaki, G.Aneural codingschemeformedbythe combined function Of gamma and theta oscillations. Schizophr. Bull. 34, 974-980 (2008).
104. Sirota, A. et al. Entrainment of neocortical neurons and gamma oscillations by the Hippocampal theta rhythm. Neuron 60, 683-697 (2008).
105. Homayoun, H.&Moghaddam, B.NMDAreceptor hypofunctionproduces opposite Effects on prefrontal cortex interneurons and pyramidal neurons. J. Neurosci. 27, 11496-11500 (2007).
106. Ito, H. T. & Schuman, E. M. Frequency-dependent gating of synaptic transmission And plasticity by dopamine. Front Neural Circuits 1, 1 (2007).
107. Cho, R. Y., Konecky, R. O. & Carter, C. S. Impairments in frontal cortical gamma Synchrony and cognitive control in schizophrenia. Proc. Natl Acad. Sci. USA 103, 19878-19883 (2006).
108. Hong, L. E. et al. Sensory gating endophenotype based on its neural oscillatory Pattern and heritability estimate. Arch. Gen. Psychiatry 65, 1008-1016 (2008).
109. Markram, H., Lubke, J., Frotscher, M.& Sakmann, B. Regulation of synaptic efficacy By coincidence of postsynaptic APs and EPSPs. Science 275, 213-215 (1997).
110. Gurden, H., Tassin, J. P. & Jay, T. M. Integrity of the mesocortical dopaminergic System is necessary for complete expression of in vivo hippocampal-prefrontal Cortex long-term potentiation. Neuroscience 94, 1019-1027 (1999).
111. Uhlhaas, P. J. et al. The development of neural synchrony reflects late maturation Andrestructuringoffunctional networksinhumans. Proc. Natl Acad. Sci.USA 106, 9866-9871 (2009).
112. Giorgio, A. et al. Longitudinal changes in grey and white matter during Adolescence. Neuroimage 49, 94-103 (2010).